Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. 

Tavotek has a rich pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases. 

Company management and advisors are veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for Biologics:

· TBE – monoclonal and multispecific antibodies against unique targets;

· TIM – novel synthetic biologic design for auto-immune diseases and chronic viral infections

· MIP – unique multi-cyclic peptides with great potency targeting intra-cellular protein-protein interactions

Tavotek has a rich and diverse pipeline across multiple therapeutic areas. It has the global angle with operations in Asia and North America. 

Tavotek’s development strategy includes organic growth, biopharma collaboration, and potential clinical stage asset licensing.